245 related articles for article (PubMed ID: 15561848)
1. n-6 polyunsaturated fatty acids enhance the activities of ceftazidime and amikacin in experimental sepsis caused by multidrug-resistant Pseudomonas aeruginosa.
Giamarellos-Bourboulis EJ; Mouktaroudi M; Adamis T; Koussoulas V; Baziaka F; Perrea D; Karayannacos PE; Giamarellou H
Antimicrob Agents Chemother; 2004 Dec; 48(12):4713-7. PubMed ID: 15561848
[TBL] [Abstract][Full Text] [Related]
2. Clarithromycin is an effective immunomodulator when administered late in experimental pyelonephritis by multidrug-resistant Pseudomonas aeruginosa.
Giamarellos-Bourboulis EJ; Antonopoulou A; Raftogiannis M; Koutoukas P; Tsaganos T; Tziortzioti V; Panagou C; Adamis T; Giamarellou H
BMC Infect Dis; 2006 Feb; 6():31. PubMed ID: 16504031
[TBL] [Abstract][Full Text] [Related]
3. Immunomodulatory clarithromycin treatment of experimental sepsis and acute pyelonephritis caused by multidrug-resistant Pseudomonas aeruginosa.
Giamarellos-Bourboulis EJ; Adamis T; Laoutaris G; Sabracos L; Koussoulas V; Mouktaroudi M; Perrea D; Karayannacos PE; Giamarellou H
Antimicrob Agents Chemother; 2004 Jan; 48(1):93-9. PubMed ID: 14693524
[TBL] [Abstract][Full Text] [Related]
4. Experimental sepsis using Pseudomonas aeruginosa: the significance of multi-drug resistance.
Giamarellos-Bourboulis EJ; Koussoulas V; Panagou C; Adamis T; Baziaka F; Skiadas I; Perrea D; Dionyssiou-Asteriou A; Giamarellou H
Int J Antimicrob Agents; 2004 Oct; 24(4):357-61. PubMed ID: 15380261
[TBL] [Abstract][Full Text] [Related]
5. Ex vivo synergy of arachidonate-enriched serum with ceftazidime and amikacin on multidrug-resistant Pseudomonas aeruginosa.
Giamarellos-Bourboulis EJ; Plachouras D; Skiathitis S; Raftogiannis M; Dionyssiou-Asteriou A; Dontas I; Karayannacos PE; Giamarellou H
J Antimicrob Chemother; 2003 Feb; 51(2):423-6. PubMed ID: 12562715
[TBL] [Abstract][Full Text] [Related]
6. Oleuropein: a novel immunomodulator conferring prolonged survival in experimental sepsis by Pseudomonas aeruginosa.
Giamarellos-Bourboulis EJ; Geladopoulos T; Chrisofos M; Koutoukas P; Vassiliadis J; Alexandrou I; Tsaganos T; Sabracos L; Karagianni V; Pelekanou E; Tzepi I; Kranidioti H; Koussoulas V; Giamarellou H
Shock; 2006 Oct; 26(4):410-6. PubMed ID: 16980890
[TBL] [Abstract][Full Text] [Related]
7. Angiopoietin-2 enhances survival in experimental sepsis induced by multidrug-resistant Pseudomonas aeruginosa.
Tzepi IM; Giamarellos-Bourboulis EJ; Carrer DP; Tsaganos T; Claus RA; Vaki I; Pelekanou A; Kotsaki A; Tziortzioti V; Topouzis S; Bauer M; Papapetropoulos A
J Pharmacol Exp Ther; 2012 Nov; 343(2):278-87. PubMed ID: 22859861
[TBL] [Abstract][Full Text] [Related]
8. The significance of oxidant/antioxidant balance for the pathogenesis of experimental sepsis by multidrug-resistant Pseudomonas aeruginosa.
Koussoulas V; Giamarellos-Bourboulis EJ; Adamis T; Mouktaroudi M; Sabracos L; Perrea D; Giamarellou H; Dionyssiou-Asteriou A
Prostaglandins Leukot Essent Fatty Acids; 2005 Jan; 72(1):41-7. PubMed ID: 15589398
[TBL] [Abstract][Full Text] [Related]
9. In vivo efficacy of continuous infusion versus intermittent dosing of ceftazidime alone or in combination with amikacin relative to human kinetic profiles in a Pseudomonas aeruginosa rabbit endocarditis model.
Robaux MA; Dube L; Caillon J; Bugnon D; Kergueris MF; Navas D; Le Conte P; Baron D; Potel G
J Antimicrob Chemother; 2001 May; 47(5):617-22. PubMed ID: 11328773
[TBL] [Abstract][Full Text] [Related]
10. Pharmacodynamics of ceftazidime administered as continuous infusion or intermittent bolus alone and in combination with single daily-dose amikacin against Pseudomonas aeruginosa in an in vitro infection model.
Cappelletty DM; Kang SL; Palmer SM; Rybak MJ
Antimicrob Agents Chemother; 1995 Aug; 39(8):1797-801. PubMed ID: 7486921
[TBL] [Abstract][Full Text] [Related]
11. Continuous administration of PBP-2- and PBP-3-specific beta-lactams causes higher cytokine responses in murine Pseudomonas aeruginosa and Escherichia coli sepsis.
Buijs J; Dofferhoff AS; Mouton JW; van der Meer JW
J Antimicrob Chemother; 2007 May; 59(5):926-33. PubMed ID: 17395686
[TBL] [Abstract][Full Text] [Related]
12. Impact of n-6 polyunsaturated fatty acids on growth of multidrug-resistant Pseudomonas aeruginosa: interactions with amikacin and ceftazidime.
Giamarellos-Bourboulis EJ; Grecka P; Dionyssiou-Asteriou A; Giamarellou H
Antimicrob Agents Chemother; 2000 Aug; 44(8):2187-9. PubMed ID: 10898699
[TBL] [Abstract][Full Text] [Related]
13. Clarithromycin is an effective immunomodulator in experimental pyelonephritis caused by pan-resistant Klebsiella pneumoniae.
Giamarellos-Bourboulis EJ; Tziortzioti V; Koutoukas P; Baziaka F; Raftogiannis M; Antonopoulou A; Adamis T; Sabracos L; Giamarellou H
J Antimicrob Chemother; 2006 May; 57(5):937-44. PubMed ID: 16549515
[TBL] [Abstract][Full Text] [Related]
14. Immunomodulatory intervention in sepsis by multidrug-resistant Pseudomonas aeruginosa with thalidomide: an experimental study.
Giamarellos-Bourboulis EJ; Bolanos N; Laoutaris G; Papadakis V; Koussoulas V; Perrea D; Karayannacos PE; Giamarellou H
BMC Infect Dis; 2005 Jun; 5():51. PubMed ID: 15978135
[TBL] [Abstract][Full Text] [Related]
15. Antimicrobial therapy and control of multidrug-resistant Pseudomonas aeruginosa bacteremia in a teaching hospital in Taiwan.
Leung CH; Wang NY; Liu CP; Weng LC; Hsieh FC; Lee CM
J Microbiol Immunol Infect; 2008 Dec; 41(6):491-8. PubMed ID: 19255693
[TBL] [Abstract][Full Text] [Related]
16. In vitro activity of polyunsaturated fatty acids on Pseudomonas aeruginosa: relationship to lipid peroxidation.
Giamarellos-Bourboulis EJ; Grecka P; Dionyssiou-Asteriou A; Giamarellou H
Prostaglandins Leukot Essent Fatty Acids; 1998 Apr; 58(4):283-7. PubMed ID: 9654401
[TBL] [Abstract][Full Text] [Related]
17. Clarithromycin co-administered with amikacin attenuates systemic inflammation in experimental sepsis with Escherichia coli.
Giamarellos-Bourboulis EJ; Baziaka F; Antonopoulou A; Koutoukas P; Kousoulas V; Sabracos L; Panagou C; Perrea D; Giamarellou H
Int J Antimicrob Agents; 2005 Feb; 25(2):168-72. PubMed ID: 15664488
[TBL] [Abstract][Full Text] [Related]
18. Antimicrobial resistance and genetic characterization of fluoroquinolone resistance of Pseudomonas aeruginosa isolated from canine infections.
Rubin J; Walker RD; Blickenstaff K; Bodeis-Jones S; Zhao S
Vet Microbiol; 2008 Sep; 131(1-2):164-72. PubMed ID: 18395369
[TBL] [Abstract][Full Text] [Related]
19. Analysis of resistance, cross-resistance and antimicrobial combinations for Pseudomonas aeruginosa isolates from 1997 to 2009.
Master RN; Clark RB; Karlowsky JA; Ramirez J; Bordon JM
Int J Antimicrob Agents; 2011 Oct; 38(4):291-5. PubMed ID: 21737249
[TBL] [Abstract][Full Text] [Related]
20. A laboratory evaluation of antibiotic therapy for ciprofloxacin-resistant Pseudomonas aeruginosa.
Rhee MK; Kowalski RP; Romanowski EG; Mah FS; Ritterband DC; Gordon YJ
Am J Ophthalmol; 2004 Aug; 138(2):226-30. PubMed ID: 15289131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
